Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 10,701–10,800 of 15,747
Augmented Artificial Intelligence
Kejriwal, M. (2022) · Future of business and finance · doi:10.1007/978-3-031-19039-1_4 · Cited by 5
Waning immune responses against SARS-CoV-2 among vaccinees in Hong KongPreprint
Peng, Q., Zhou, R., Wang, Y., Zhao, M., Liu, N., Li, S., Huang, H., Yang, D., Au, K., Wang, H., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.22.473934 · Cited by 3
Myocardial Injury Related to SARS-CoV-2 mRNA Vaccination: The Plot Thickens
Levi, N., & Hasin, T. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.3013 · Cited by 3
Ukey, R., Bruiners, N., Mishra, H., Mishra, P., McCloskey, D., Onyuka, A., Chen, F., Pinter, A., Weiskopf, D., Sette, A., et al. (2021) · medRxiv · doi:10.1101/2021.09.17.21263528
Review of current vaccine development platform to prevent coronavirus disease
Arif, K., Malhotra, S., Mohammad, S., Fatima, S., Farooqui, S., & Saleem, M. (2022) · National Journal of Maxillofacial Surgery · doi:10.4103/njms.njms_454_21 · Cited by 3
“it was 91% reaching full efficacy against disease with onset at least 7 days after dose.[14] Most of the reported adverse reactions were mild or moderate in severity and resolved in the first 7 days after each BNT162b1 dose for the prime and boost vaccinations.”
BackgroundArabic Twitter Conversation Dataset about the COVID-19 Vaccine
Alhazmi, H. (2022) · Data · doi:10.3390/data7110152 · Cited by 3
“The development and production of vaccines [10] offered a potential solution to controlling the pandemic.”
Ein Virus und seine Folgen: COVID-19 und Long Covid – ein hybrides Krankheitsmodell
Richter, D., & Theodoridou, A. (2023) · Psychiatrische Praxis · doi:10.1055/a-2168-4553 · Cited by 3
“Diese Perspektive könnte zu ver-stehen helfen, warum 20 bis 30 Prozent der Menschen in den Pla-cebo-Gruppen in den großen Wirksamkeits-Studien der BioNTech/ Pfizer-und Moderna-Vakzine über Fatigue-Symptome nach der Impfung berichtet haben [20].”
BackgroundClinical observation and analysis of skin reactions caused by COVID‐19 vaccination
Li, Y., Fan, L., Mao, Q., Luan, X., Wang, Z., Zeng, N., Cheng, Y., Li, Y., Xia, Q., Lu, Z., et al. (2022) · Dermatologic Therapy · doi:10.1111/dth.15746 · Cited by 3
“However, in a sense, vaccines are also drugs and can cause adverse reactions in humans.(10) As for the mechanism of adverse reactions caused by vaccines, the leading cause is the immune response; vaccines act as an antigen and stimulate the body to produce an immune response.”
BackgroundTatsi, E., Filippatos, F., Bello, T., Syriopoulou, V., & Michos, A. G. (2024) · Pathogens · doi:10.3390/pathogens13040284 · Cited by 2
“The utilization of T-cell repertoire sequencing could facilitate the identification and characterization of T-cell responses that are specific to COVID-19, provide valuable information regarding infection and immunization and support the optimization of vaccination strategies.”
MethodLiu, S., Wang, P., Shi, X., Weng, T., Zhong, J., Zhang, X., Qu, J. T., Chen, L., Xu, Q., Meng, X., et al. (2023) · Journal of Medical Virology · doi:10.1002/jmv.29125 · Cited by 3
Li, K., Wu, Y., Zhang, H., Chen, S., Wu, B., Li, T., Li, E., Luo, F., Jin, A., Zhang, B., et al. (2024) · Journal of Medical Virology · doi:10.1002/jmv.70134 · Cited by 3
“Several vaccines have been licensed, such as inactivated vaccines [1, 2], mRNA vaccines [3, 4], recombinant adenovirus vector vaccines [5, 6] and protein subunit vaccines [7].”
COVID-19, the Future Vaccine and What It Means for Cancer Patients on Immunotherapy
El-Shakankery, K. H., Kefas, J., & Miller, R. E. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.631611 · Cited by 3
Estimation and interpretation of vaccine efficacy in COVID-19 randomized clinical trials
Michiels, H., Vandebosch, A., & Vansteelandt, S. (2022) · Statistical Communications in Infectious Diseases · doi:10.1515/scid-2022-0003 · Cited by 3
Kim, H., Bershteyn, A., McGillen, J. B., et al. (2023) · BMC Public Health · doi:10.1186/s12889-022-14846-7 · Cited by 3
“Vaccine efficacy was assumed to reach 95% starting 11 days after vaccination [23] and last at least 6.”
BackgroundWolfe, D., Arangies, E., David, G. L., Armstrong, B., Scocca, T. Z., Fedler, J. K., Natarajan, R., Zhou, J., Jayashankar, L., Donis, R. O., et al. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae286 · Cited by 6
Chang, Y.-S., Kai, H., Lee, J. M., Vagts, C. L., Ascoli, C., Amin, M. R., Ghassemi, M., Lora, C. M., Edafetanure-Ibeh, R., Huang, Y., et al. (2024) · eLife · doi:10.7554/elife.83641 · Cited by 4
“The COVID-19 mRNA-based vaccines, BNT162b2 and mRNA-1273, have proven to be efficacious in non-immunocompromised individuals, with initial reports showing 95 and 94.1% reduction of COVID-19 disease in recipients ( Baden et al., 2021 ; Polack et al., 2020 ).”
ResultInfluentialKanizsai, A., Závori, L., Molnár, T., Tökés‐Füzesi, M., Szalai, Z., Berecz, J., Várnai, R., Péterfi, Z., Schwarcz, A., & Csécsei, P. (2023) · Vaccines · doi:10.3390/vaccines11010182 · Cited by 5
“Similar to a previous study [1], we also observed that systemic adverse reactions were reported more often by the younger volunteers than the older ones.”
BackgroundResultLiu, W.-D., Lin, M.-S., Sun, H., Shih, M., Chuang, Y., Huang, Y., Lin, K., Li, G.-C., Wu, P., Chen, L.-Y., et al. (2024) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2024.02.004 · Cited by 3
Wolz, O., Vahrenhorst, D., Quintini, G., Lemberg, C., Koch, S. D., Kays, S.-K., Walz, L., Kulkarni, N., Fehlings, M., Wengenmayer, P., et al. (2024) · Vaccines · doi:10.3390/vaccines12040388 · Cited by 3
“…was a global pandemic, Comirnaty BNT162b2 (BioNTech/Pfizer) and Spikevax mRNA-1273 (Moderna) mRNA vaccines were approved for use around the world [1–3] mRNA technology platform has allowed for the rapid development and production of vaccines with the flexibility to be adjusted to new variants.”
BackgroundCOVID‐19 Vaccine mRNA Biodistribution: Maternal and Fetal Exposure Risks
Zhong, C., Cohen, K., Lin, X., Schiller, E. A., Sharma, S., & Hanna, N. N. (2024) · American Journal of Reproductive Immunology · doi:10.1111/aji.13934 · Cited by 5
“Currently, the two major COVID-19 vaccines, Pfizer BNT162b2 and Moderna mRNA-1273 are both LNP-encapsulated mRNA vaccines that encode the SARS-CoV-2 spike glycoprotein [8, 9].”
Sejdic, A., Hartling, H. J., Holler, J. G., Gjærde, L. K., Lindegaard, B., Dungu, A. M., Gnesin, F., Møller, M. E. E., Teglgaard, R. S., Niemann, C. U., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1360843 · Cited by 3
Synthesis of hydrophobic-tagged 2′-deoxy-modified cap analogs and its effect on mRNA translation
Meng, Z., Nakashima, Y., Inagaki, M., Li, Z., Acharyya, S., Hashiya, F., Abe, N., Kimura, Y., & Abe, H. (2025) · Bulletin of the Chemical Society of Japan · doi:10.1093/bulcsj/uoaf006 · Cited by 5
Narasimhan, M., Mahimainathan, L., Noh, J., & Muthukumar, A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.730404 · Cited by 3
Wang, H., Daizadeh, N. S., Shen, Y. L., Chen, J., Rockhold, F. W., Pang, H., & Lee, H. (2025) · Clinical and Translational Science · doi:10.1111/cts.70328 · Cited by 4
“NCT04368728 is a Phase 1/2/3 placebo controlled, randomized, observer-blind, dose-finding study to evaluate the safety, tolerability, immunogenicity and efficacy of SARS- COV-2 RNA vaccine candidate against COVID-19 in 43,548 healthy individuals [6].”
Shurrab, F. M., Al‐Sadeq, D. W., Abou-Saleh, H., Al-Dewik, N. I. E., Elsharafi, A. E., Hamaydeh, F. M., Halawa, B. Y. A., Jamaleddin, T. M., Hameed, H. M. A., Nizamuddin, P. B., et al. (2022) · Vaccines · doi:10.3390/vaccines10020191 · Cited by 4
“BNT162b2 and mRNA-1273, obtained Emergency Use Listing (EUL) from WHO and have demonstrated a high degree of protection against the COVID-19 illness [4,5].”
BackgroundIson, M. G., Avery, R. K., Blumberg, E. A., et al. (2021) · Transplantation · doi:10.1097/tp.0000000000003747 · Cited by 3
Subaiea, G. M., Alkhateeb, N., Sahman, F., et al. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1561410 · Cited by 3
SARS-CoV-2 Vaccination for Children—An Open Issue
Caselli, D., & Aricò, M. (2021) · Pediatric Reports · doi:10.3390/pediatric13010013 · Cited by 4
Zeng, Q., Yang, X. Y., Gao, Q., Li, Y., Li, Y.-Z., Huang, G., & Xu, Y. (2023) · Vaccines · doi:10.3390/vaccines11020461 · Cited by 3
Li, J., Liu, Y., Ma, X., Liu, S., Yang, C., Zhang, Y., Cheng, X., Wen, Y., Mi, S., Zu, H., et al. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.adw6105 · Cited by 4
Matsuzono, K., & Fujimoto, S. (2024) · SAGE Open Medical Case Reports · doi:10.1177/2050313x241235830 · Cited by 3
Chen, M. Z., Yuen, D., McLeod, V. M., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.08.07.607101 · Cited by 3
“The successful deployment of two mRNA-lipid nanoparticle (LNP) vaccines to combat the COVID-19 pandemic has demonstrated the potential of LNPs to effectively deliver large synthetic mRNA payloads in vivo [2, 3].”
BackgroundDulipsingh, L., Lang, M., Diffenderfer, M. R., Cook, L., Puff, J., Diaz, L., He, L., & Schaefer, E. J. (2022) · Journal of Clinical Virology Plus · doi:10.1016/j.jcvp.2022.100130 · Cited by 3
A biomaterials viewpoint for the 2020 SARS-CoV-2 vaccine development.
Jatoi, I., & Fan, J. (2021) · PubMed Central · doi:10.3877/cma.j.issn.2096-112x.2021.01.005 · Cited by 3
Kondo, Y., Takeshita, M., Uwamino, Y., Namkoong, H., Saito, S., Kikuchi, J., Hanaoka, H., Suzuki, K., Hasegawa, N., Murata, M., et al. (2022) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2022-eular.4214 · Cited by 2
mRNA medicine for cardiovascular disease
Zhou, Z., Chen, W., Yu, H., Tabas, I. A., Foo, R., & Tao, W. (2026) · Nature Cardiovascular Research · doi:10.1038/s44161-026-00804-8 · Cited by 6
An asymptotic threshold of sufficient randomness for causal inference
Knaeble, B., Osting, B., & Tshiaba, P. (2023) · Stat · doi:10.1002/sta4.609 · Cited by 4
“The randomized controlled trial of the BNT162b2 mRNA Covid-19 Vaccine demonstrated effectiveness of the vaccine to prevent cases of Covid-19 and also severe cases of Covid-19, but the sample size was not large enough to determine whether or not the vaccine saved lives (Polack et al., 2020).”
BackgroundKobayashi, M., Mori, A., Onozawa, M., Tsukamoto, S., Senjo, H., Ishio, T., Yokoyama, E., Kanaya, M., Izumiyama, K., Saito, M., et al. (2023) · Annals of Hematology · doi:10.1007/s00277-023-05142-4 · Cited by 4
Seki, Y., Yoshihara, Y., Nojima, K., Momose, H., Fukushi, S., Moriyama, S., Wagatsuma, A., Numata, N., Sasaki, K., Kuzuoka, T., et al. (2022) · medRxiv · doi:10.1101/2022.01.20.22269587 · Cited by 6
Beymer, M. R., Gomez, S. A. Q., Santo, T. J., et al. (2022) · Journal of Community Health · doi:10.1007/s10900-022-01149-6 · Cited by 3
“This content area included: (1) self-reported COVID-19 vaccination status; (2) intention to be vaccinated (if not yet vaccinated); (3) attitudes about vaccination effectiveness (Getting the vaccine will help decrease the spread of COVID-19 in my community), safety (The vaccine is safe), and importance (Getting the vac…”
BackgroundPetrelli, F., Giannini, D., Pucci, C., Corso, I. D., Rocchi, V., Dolcher, M. P., Pieve, G., Pratesi, F., Migliorini, P., & Puxeddu, I. (2022) · International Archives of Allergy and Immunology · doi:10.1159/000526764 · Cited by 3
Lu, X., Hayashi, H., Ishikawa, E., Takeuchi, Y., Dychiao, J. V. T., Nakagami, H., & Yamasaki, S. (2024) · eLife · doi:10.7554/elife.89999 · Cited by 6
Salivary Antibody Responses to Two COVID-19 Vaccines following Different Vaccination Regimens
Alkharaan, H., Alqarni, H., Aldosari, M., Alsaloum, M., Aldakheel, G., Alenazi, M. W., & Alharbi, N. K. (2023) · Vaccines · doi:10.3390/vaccines11040744 · Cited by 3
Plaxco, A. P., Kmet, J. M., Nolan, V. G., Taylor, M. A., & Smeltzer, M. P. (2023) · AJPM Focus · doi:10.1016/j.focus.2023.100150 · Cited by 3
Analyzing COVID-19 Vaccination Side Effects Among the Adult Population in Jeddah, Saudi Arabia
Alamri, T., Anwer, F., Butt, N. S., Alganmi, A. H., Alotaibi, S. A., Alzibali, K. F., Hawsawi, H. A., Bakarman, M. A., & Malik, A. A. (2023) · Cureus · doi:10.7759/cureus.47136 · Cited by 3
“In a phase 3 trial for that vaccine, 51-59% of participants reported feeling fatigued after receiving the second dose of the Pfizer vaccine [20].”
BackgroundRhee, C., Wang, R., Ye, S., Baker, M. A., Griesbach, D., Laskowski, K. R., & Klompas, M. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab204 · Cited by 3
Bellesi, S., Sali, M., Maiolo, E., Boza, M. D. C. P., Alma, E., Palucci, I., Fatone, F., Maio, F. D., Viscovo, M., D’Alò, F., et al. (2022) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2022.2032042 · Cited by 3
Turabián, J. L. (2021) · Epidemiology International Journal · doi:10.23880/eij-16000204 · Cited by 4
Fialho, M. J., da Silva, C. J. F., Miranda, G. B. A., Assis, I. S. D. S., Moreno, A. M., de Moura, P. H., da Fonseca, A. C. P., Silva, T., & Cardozo, S. V. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1667392 · Cited by 3
Development of Focused Ultrasound-Assisted Nanoplexes for RNA Delivery
Ranjan, S. K., Bosch, S., Lukkari, H., Schirmer, J., Aaltonen, N., Nieminen, H. J., Lehto, V., Urtti, A. O., Lajunen, T., & Rilla, K. J. (2024) · Nanomaterials · doi:10.3390/nano14131089 · Cited by 3
“The increased CD44 expression levels upon control siRNA treatments (Figure 6) were liposome-induced stress responses or liposome-plasma membrane interactions.”
BackgroundMethodWhittle, S., Hazlewood, G. S., Robinson, P. C., Johnston, R. V., Leder, K. S., Glennon, V., Avery, J., Grobler, L., & Buchbinder, R. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd014991 · Cited by 3
A case of restless legs syndrome after BNT162b2 mRNA COVID ‐19 vaccination
Ito, H., Kuroki, T., Horiuchi, S., & Shinya, Y. (2022) · Neurology and Clinical Neuroscience · doi:10.1111/ncn3.12594 · Cited by 2
A Historical Overview on mRNA Vaccine Development
Verbeke, R., Cheng, M. H. Y., & Cullis, P. R. (2024) · Wiley eBooks · doi:10.1002/9783527838394.ch1 · Cited by 9
Transmissibility of COVID-19 among Vaccinated Individuals: A Rapid Literature Review - Update #1Preprint
Egunsola, O., Mastikhina, L., Dowsett, L. E., Farkas, B., Hofmeister, M., Saxinger, L. M., & Clement, F. M. (2021) · medRxiv · doi:10.1101/2021.06.29.21255526 · Cited by 4
Leal, L., Pich, J., Ferrer, L., Nava, J., Martí‐Lluch, R., Esteban, I., Pradenas, E., Regué, D. R., Prenafeta, A., Escobar, K., et al. (2022) · medRxiv · doi:10.1101/2022.08.09.22278560 · Cited by 3
Tardiolo, G., Brianti, P., Sapienza, D., dell’Utri, P., Dio, V. D., Rao, G., & Calabrò, R. S. (2021) · Medical Sciences · doi:10.3390/medsci9030053 · Cited by 3
“Then, following another pivotal efficacy trial [67], in which 43,548 people aged > 16 years received two doses of either placebo or BNT162b2, the vaccine was conditionally authorized for marketing by the European Commission [67].”
Background[Bell's Palsy Secondary to COVID-19 Vaccine Pfizer: Case report].
González-Enríquez, J. O. (2022) · PubMed Central · Cited by 6
Xu, L., Chen, R., Wang, X., Liu, D., Liu, Y., & Zhao, C. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202501914 · Cited by 5
Efficacy of early use of remdesivir: a systematic review of subgroup analysis
Gil‐Sierra, M. D., Briceño-Casado, M. D. P., Rey, E. J. A. D., & Sánchéz‐Hidalgo, M. (2022) · Revista Española de Quimioterapia · doi:10.37201/req/154.2021 · Cited by 4
Advances in microbubble-assisted ultrasound-guided gene therapy: Mechanisms and applications
Tie, Z., Zhang, S., Qu, Y., Wang, M., Liu, R., Sun, D., & Dai, Z. (2024) · Science China Materials · doi:10.1007/s40843-024-2993-4 · Cited by 4
“Typical delivery forms include naked nucleic acid molecules, viral vector-mediated gene delivery, encapsulated lipid nanoparticles, etc. [3–9].”
Sayed, T. M., Arshad, S. H., Aalam, M., Khan, F., & Majeed, S. (2021) · Pakistan Journal of Medical and Health Sciences · doi:10.53350/pjmhs211592789 · Cited by 3
Tummolo, A., Dicintio, A., Paterno, G., Carella, R., Melpignano, L., & Giovanni, D. D. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph191912227 · Cited by 4
Gounder, P. P., Saint, M. R., Larios, C. A., et al. (2021) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2021.420 · Cited by 3
Nkosi, T., Chasara, C., Mbatha, A., Nsimbi, M., Papadopoulos, A. O., Nguni, T. L., Karim, F., Moosa, M. Y. S., Gazy, I., Jambo, K., et al. (2022) · medRxiv · doi:10.1101/2022.04.05.22273453 · Cited by 3
Recurrent Aseptic Meningoencephalitis Following BNT162b2 Vaccination for COVID-19
Kang, K., Lee, J., & Kim, B. (2022) · Journal of Clinical Neurology · doi:10.3988/jcn.2022.18.6.723 · Cited by 3
Iacono, S., Stefano, V. D., Alonge, P., Vinciguerra, C., Milella, G., Caputo, F., Lasorella, P., Neto, G., Pignolo, A., Angelo, T., et al. (2022) · Brain Sciences · doi:10.3390/brainsci12101396 · Cited by 4
“Among the general population, the most common AE following BNT162b2 is local pain (66–83%), followed by fatigue (51–59%), cephalalgia (25–52%), myalgia (19–37%), and gastrointestinal symptoms (8–12%) [21], with a higher prevalence in younger people.”
BackgroundRasmussen, M., Neumann, A., Moghaddassi, M., Inghammar, M., Björk, J., Malmqvist, U. P., & Kahn, F. (2025) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2025.2479139 · Cited by 2
mRNA-based COVID-19 vaccines: a new age
Martínez-Espinosa, R. R., & Ramírez-Vélez, G. (2021) · Proceedings of Scientific Research Universidad Anáhuac Multidisciplinary Journal of Healthcare · doi:10.36105/psrua.2021v1n2.03 · Cited by 2
Long-term observation of antibody titers against SARS-CoV-2 following vaccination
Sugiyama, K., Suzuki, C., Aoyama, M., TOYOTA, N., Nakagawa, N., Shozu, M., Nakai, K., & Iwano, K. (2022) · Public Health in Practice · doi:10.1016/j.puhip.2022.100297 · Cited by 3
“SARS-CoV-2 mRNA vaccines, which induce neutralizing antibodies against the spike protein of SARS-CoV-2, were developed rapidly [1].”
BackgroundCarroll, H. A., Millar, E., & Deans, K. A. (2022) · Research Square · doi:10.21203/rs.3.rs-1425014/v1 · Cited by 4
Morimoto, T., Morikawa, T., Imura, H., Nezu, M., Hamazaki, K., Sakuma, M., & Nakamura, T. (2026) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2026.01.002 · Cited by 7
Palmer, M., Seekins, D. W., Avigan, M., MARCINAK, J. F., Rockey, D. C., Regev, A., Shastri, V. K., Lewis, J. H., & Dash, A. (2025) · Drug Safety · doi:10.1007/s40264-025-01591-0 · Cited by 2
“These reports began to appear shortly after the advent of safe and effective vaccines against SARS-CoV-2 in Dec 2021, even though no cases of DILI were seen during their clinical development [98].”
Chyzh, O. V. (2023) · The Journal of Politics · doi:10.1086/726933 · Cited by 3
Gennari, A. G., Rossi, A., Sartoretti, T., Maurer, A. B., Skawran, S., Treyer, V., Sartoretti, E., Fontecedro, A. C., Schwyzer, M., Waelti, S. L., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-44215-2 · Cited by 3
Martínez, D. A. S., Cerame, Á., Mirallas, O., Cabezudo, L., Ciprés, M., Calle, D. G., Meler‐Claramonte, C., Hernando, I., & Carrasco, J. P. (2022) · Revista Española de Educación Médica · doi:10.6018/edumed.506821 · Cited by 3
Bressy, C., Zemani, A., Goyal, S., Jishkariani, D., Lee, C. N., & Chen, Y. H. (2022) · PLoS ONE · doi:10.1371/journal.pone.0276905 · Cited by 4
Yang, Z., Han, Y., Ding, S., Finzi, A., Mothes, W., & Lu, M. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.10.11.463956 · Cited by 3
Prior SARS-CoV-2 infection affects adaptive immune responses to Omicron BA.4/BA.5 mRNA booster
Wachter, B. T., Xu, Q., Shi, L., Burbelo, P. D., Myint-Hpu, K., Schwartzberg, P. L., Rehman, M. T., Dewar, R. L., Boswell, K. L., Koup, R. A., et al. (2025) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2025.02.026 · Cited by 4
Amstutz, A., Chammartin, F., Audigé, A., Eichenberger, A. L., Braun, D. L., Amico, P., Stoeckle, M. P., Hasse, B. K., Papadimitriou‐Olivgeris, M., Manuel, O., et al. (2024) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiae291 · Cited by 7
“Both vaccines were tested in large randomized clinical trials among the general population where they have proven to be safe and effective in terms of preventing COVID-19 infections [5, 6].”
BackgroundReplicability of studies following a dual‐criterion design
Rosenkranz, G. K. (2021) · Statistics in Medicine · doi:10.1002/sim.9014 · Cited by 4
Zona, E. E., Gibes, M. L., Jain, A. S., Danobeitia, J. S., Garonzik‐Wang, J., Smith, J. A., Mandelbrot, D. A., & Parajuli, S. (2024) · Critical Care Research and Practice · doi:10.1155/2024/7140548 · Cited by 4
Berg, S. K., Wallach‐Kildemoes, H., Rasmussen, L. R., Nygaard, U., Bundgaard, H., Ersbøll, A. K., Bering, L., Thygesen, L. C., Nielsen, S. D., & Christensen, A. V. (2023) · Vaccines · doi:10.3390/vaccines11121766 · Cited by 3
Mohamed, K. M., Álvarez-Hernández, M. P., García, C. J., Guevara‐Hoyer, K., Freites, D., Prada, C. M., Pérez-Sancristóbal, I., Fernández‐Gutiérrez, B., Chaín, G. M., Rodero, M., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11092418 · Cited by 4
Reimann, H., Moosmann, C., Schober, K., Lang, V., Verhagen, J., Zeun, J., Mackensen, A., Kremer, A. N., Völkl, S., & Aigner, M. (2023) · Immunobiology · doi:10.1016/j.imbio.2023.152720 · Cited by 2
Transient Myopericarditis Following Vaccination for COVID-19
Gill, J., Mallari, A. J. P., & Zahra, F. (2022) · Journal of Medical Cases · doi:10.14740/jmc3876 · Cited by 4
“1% protection against SARSCoV-2, respectively [7-9].”
Background(2021) · doi:10.1101/2021.08.12.21261976 · Cited by 3
“The severe adverse side effects as defined by Polack et al.[17] or any clinical manifestation potentially correlated with the vaccination were also recorded for all the investigated patients or subjects.”
BackgroundDetection of immunoglobulin response to COVID-19 vaccination using a novel rapid fingerstick assay
Cobb, B. L., & Sawalha, A. H. (2021) · Clinical Immunology · doi:10.1016/j.clim.2021.108791 · Cited by 3
“2 has a reported efficacy of 95% for persons 16 years or older from 7 days after Dose 2 in participants without evidence of prior SARS-CoV-2 infection [3].”
Aldali, H. J., Aldali, J. A., Alotaibi, B. A., Alasiri, G. A., Alromih, A. M., Elsokkary, E. M., Aldali, A. Z., & Almeziny, A. (2023) · Vaccines · doi:10.3390/vaccines11020266 · Cited by 3
“Several mild to moderate side effects, such as headaches, pain, swelling, and redness at the injection site, as well as muscle and joint aches, were associated with the side effects of the COVID-19 vaccinations [9,15,16].”
BackgroundResultAkhter, M., Roy, S. K., Khair, A., Karim, M. R., Mojlish, U. K. F. K., Ahmed, M. U., & Ali, L. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e37287 · Cited by 3
Structural immunotherapy: Harnessing chemical design to build powerful next-generation therapeutics
Teplensky, M. H., Bourgeois, J. N., Kudruk, S., Petrosko, S. H., & Mirkin, C. A. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2409553122 · Cited by 3
Evidence of immune imprinting or the effect of selection bias?
Hansen, C. H. (2023) · Science Advances · doi:10.1126/sciadv.adk5668 · Cited by 3
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.